Veronique Blanc

USPTO Granted Patents = 10 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 8.8

ph-index = 3

Forward Citations = 76(Granted Patents)

Company Filing History:

Rhone-poulenc Rorer S.a.

7. 1 out of 832,843

Other

patents

Years Active: 1999-2018

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE47123 - EPHA2 receptor antagonist antibodies (2018-11-12),

2. 9011863 - Combinations of kinase inhibitors for the treatment of cancer (2015-04-21),

3. 8992912 - Methods of use for antibodies that specifically bind to the EphA2 receptor (2015-03-31),

4. 8460667 - EPHA2 receptor antagonist antibodies (2013-06-11),

5. 8153765 - Anti-CD38 antibodies for the treatment of cancer (2012-04-10),

6. 7090999 - Polypeptides involved in the biosynthesis of streptogramins, nucleotide sequences coding for these polypeptides and their use (2006-08-15),

7. 6670157 - Polypeptides involved in the biosynthesis of streptogramins, nucleotide sequences coding for these polypeptides and their use (2003-12-30),

8. 6171846 - Polypeptides involved in the biosynthesis of streptogramins, nucleotide sequences coding for these polypeptides and their use (2001-01-09),

9. 6077699 - Polypeptides involved in the biosynthesis of streptogramins, nucleotide (2000-06-20),

10. 5891695 - Polypeptides involved in the biosynthesis of streptogramins, nucleotide (1999-04-06),

Title: Veronique Blanc: Innovator in Antibody Therapeutics

Introduction

Veronique Blanc is a prominent inventor based in Paris, France. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 10 patents, her work focuses on innovative solutions for treating various diseases, including cancer.

Latest Patents

Among her latest patents is the development of EPHA2 receptor antagonist antibodies. These antagonistic antibodies specifically bind to and inhibit Class A Eph receptors, providing new avenues for therapeutic interventions. Additionally, she has created methods for treating cancer through combinations of kinase inhibitors, which involve administering a compound that targets HER2 and/or HER3, enhancing treatment efficacy.

Career Highlights

Veronique has worked with notable companies such as Sanofi and Aventis Pharma S.A. Her experience in these leading pharmaceutical firms has allowed her to refine her expertise in drug development and innovation.

Collaborations

Throughout her career, Veronique has collaborated with esteemed colleagues, including Francis Blanche and Joel Crouzet. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Veronique Blanc stands out as a key figure in the field of antibody therapeutics, with a strong portfolio of patents and a commitment to advancing medical science. Her innovative work continues to pave the way for new treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.